DUBLIN--(BUSINESS WIRE)--The "Global Premature Ejaculation Treatment Market 2017-2021" report has been added to Research and Markets' offering.
The global premature ejaculation treatment market to grow at a CAGR of 8.71% during the period 2017-2021.
Global Premature Ejaculation Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendors operating in this market. To calculate the market size, the report considers the sales of branded, generic, and off-label drugs.
The global premature ejaculation treatment market has witnessed the increased use of off-label drugs belonging to different drug classes such as SSRIs (fluvoxamine, paroxetine, sertraline, and fluoxetine) and PDE5 inhibitors (Cialis, VIAGRA, and Levitra). Pharmacological modification of the ejaculatory response in patients with the condition represents a novel approach for the treatment of premature ejaculation and will lead to the gradual replacement of psychosexual counseling, which was previously regarded as the cornerstone of premature ejaculation treatment.
Key Market Trends
- Growing online retail sales of drugs
- Increase in awareness of premature ejaculation
- New treatment methods
Key vendors
- Absorption Pharmaceuticals
- Bayer
- Eli Lilly
- Regent Pacific Group
Other prominent vendors
- Dong-A Pharmaceutical
- Emcure
- Futura Medical
- GlaxoSmithKline
- NeuroHealing Pharmaceuticals
- Pfizer
Key Topics Covered:
Part 01: Executive Summary
Part 02: Scope Of The Report
Part 03: Research Methodology
Part 04: Introduction
Part 05: Premature Ejaculation: Disease Overview
Part 06: Market Landscape
Part 07: Pipeline Landscape
Part 08: Market Segmentation By Route Of Administration
Part 09: Market Segmentation By Drug Class
Part 10: Regional Landscape
Part 11: Decision Framework
Part 12: Drivers And Challenges
Part 13: Market Trends
Part 14: Vendor Landscape
Part 15: Key Vendor Analysis
Part 16: Appendix
For more information about this report visit https://www.researchandmarkets.com/research/5ztq8j/global_premature